Patent families
A portfolio spanning 38 countries.
Investors & partners
One platform.
Concrete opportunities.
Bone regeneration at the heart of our development: a lead Bionacre® programme, an Ostenova range preparing for launch, and an established dermo-cosmetic activity.
Patents & publications
A protected, documented
scientific foundation.
A scientific foundation built around nacre, its properties and its applications.
Scientific publications
By MEGA BIOPHARMA and its collaborators.
Tissue repair markets
Lasting needs.
Growing markets.
Three global benchmarks for the fields in which we are developing the Bionacre® platform.
Dental bone grafts & substitutes
901.1US$M
Estimated global market in 2025
+9.1% per year · 2026–2033
Source: Grand View ResearchBone grafts & substitutes, all applications
3.3US$B
Estimated global market in 2025
+5.6% per year · 2026–2033
Source: Grand View ResearchCartilage repair
5.98US$B
Estimated global market in 2024
+5.1% per year · 2025–2030
Source: Grand View ResearchSector estimates and forecast annual growth rates. These markets overlap and should not be added together; they do not represent MEGA BIOPHARMA’s directly addressable market.
BIONACRE® BONE GRAFT / PROGRAMME STATUS
From preclinical development
to the next milestones.
Late preclinical stage
Bionacre® Bone Graft is in the final stage of preclinical development.
Clinical investigation
Applications to conduct a clinical investigation in Europe are being prepared.
Planned 510(k) submission
A submission to the FDA is planned for early 2027. This milestone is prospective.
Status communicated by MEGA BIOPHARMA in September 2026. Submitting a dossier does not constitute market authorisation.
MEGA Dental · Distribution
From research
to practitioners.
MEGA BIOPHARMA and MEGA Dental share the same founder, Joël Drai, and roots in the dental sector.
MEGA BIOPHARMA develops biomaterials. MEGA Dental, a distributor of dental products and equipment, contributes its understanding of dental practices and its distribution network in France.
This network will support the future distribution of Bionacre® Bone Graft, subject to the necessary authorisations.
Discover MEGA Dental ↗Investors & partners
Nature creates.
Science reveals.
Nature created nacre’s architecture. Science is revealing its potential. With Bionacre®, we are developing this inspiration into regenerative technology. Let’s discuss scientific collaboration, industry partnerships and the next milestones.
Coming soon
Ostenova
A porcine-derived bone substitute being prepared for launch.Late 2026 · planned
Ostenova Membrane
Planned launch of collagen membranes in three sizes.Early 2027 · planned
Bionacre® Bone Graft
Programme in late preclinical development. US 510(k) submission planned under the timeline communicated in September 2026.Request the investor presentation
Programmes, evidence and industrial strategy.
investisseurs@megabiopharma.com